Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Actavis Group, a generic pharmaceutical company, has received approval from the FDA to market levetiracetam oral solution. Distribution of the product has commenced.
Subscribe to our email newsletter
Levetiracetam oral solution is available in the 100mg/ml strength and is the generic equivalent of Keppra oral solution by UCB. Levetiracetam oral solution is used in the treatment of partial onset seizures in adults and children with epilepsy.
Doug Boothe, CEO of Actavis in the US, said: “The approval of levetiracetam oral solution demonstrates our continuing commitment to introduce new generic products to the marketplace, as well as highlights our expertise in developing and manufacturing a wide range of dosage forms.”